NetraMark Holdings Inc. and the National Institute for Mental Health (NIMH) have partnered to analyze clinical trials on ketamine for psychiatric disorders using advanced AI. This collaboration aims to improve patient selection and trial design by understanding ketamine and placebo responses, and identifying adverse events. NetraMark’s AI platform, NetraAI, is specifically designed to handle small, complex datasets, improving predictive model accuracy and providing deeper insights into the mechanisms of action for ketamine. This initiative signifies the growing integration of AI in psychiatric research, aiming to enhance precision medicine. As AI technology advances rapidly, it is revolutionizing various sectors, including the creative industries and scientific research, with significant investments driving these developments. The future of AI, including the development of Artificial General Intelligence (AGI), promises even greater capabilities, potentially transforming clinical trial analysis by more efficiently and accurately processing complex data, improving patient stratification, and optimizing trial designs for better outcomes.
AI and Ketamine – Revolutionizing Psychiatric Treatment Research
NetraMark’s AI platform aims to enhance precision medicine in psychiatry.
1–2 minutes
TOP STORIES
The New York Times accuses Brave of illegally scraping and distributing its content …
The New York Times accuses Brave of illegally scraping and distributing its content …
The event in Brooklyn revealed a strong community backlash against AI and data centers …
The event in Brooklyn revealed a strong community backlash against AI and data centers …
A federal judge has ruled that xAI must face the NAACP lawsuit over permit violations …
A federal judge has ruled that xAI must face the NAACP lawsuit over permit violations …
